Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC101 for delaying CKD progression in metabolic acidosis (Phase 3b, randomized, double-blind, placebo-controlled)
2018-001303-36Phase 3Completed
- Sponsor
- Tricida, Inc.
- Start
- Sep 2018
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) and metabolic acidosis comparing TRC101 with Placebo (2 arms). Primary endpoint: Progression of chronic kidney disease (primary composite endpoint). Started Sep 2018; status: completed.
02
Drugs
veverimer
03
Conditions
chronic kidney disease (CKD)metabolic acidosis
Beyond the preview
Go deeper on 2018-001303-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001303-36.